OptimizeRx (OPRX)
Nasdaq Market Closed
OptimizeRx Corporation is a digital health technology company serving the U.S. healthcare and life sciences markets. Its platform is designed to help pharmaceutical, biotech, and other healthcare organizations communicate with healthcare professionals and patients at key points in the care journey. The company operates at the intersection of healthcare marketing, clinical workflow technology, and patient engagement.
OptimizeRx’s network is embedded across a range of digital channels used by physicians and other healthcare professionals, including electronic health record and e-prescribing environments. Through these integrations, the company enables life sciences brands to deliver educational messages, therapy information, affordability support, and other resources in contexts where treatment decisions are being considered. Its tools also support direct-to-consumer outreach, allowing clients to coordinate engagement across both professional and patient audiences.
The company’s value proposition is based on relevance, timing, and measurable engagement. Rather than relying solely on traditional advertising, OptimizeRx uses data and technology to target communications to appropriate audiences while supporting compliance with healthcare industry standards. Its services can be used for product launches, adherence programs, patient acquisition campaigns, and ongoing brand support.
OptimizeRx competes in a market shaped by the digitization of healthcare, the growing importance of electronic clinical workflows, and life sciences companies’ need for more efficient commercial strategies. Its platform connects healthcare professionals, patients, and pharmaceutical brands through an omnichannel model, making it a specialized participant in the broader healthcare technology and digital marketing ecosystem.
Last updated
- Market Cap
- 92.89M
- P/E
- 13.59
- P/FCF
- 6.48
- P/S
- 0.87
- Enterprise Value
- 96.06M
- Sector
- Industrials
- Industry
- Business Services, Not Elsewhere Classified
- Address
- 260 CHARLES STREET, WALTHAM, MA, 02453
OptimizeRx Continues Expansion of the Company’s Point-Of-Care Network
OptimizeRx Corporation Confirms Receipt of Notice of Director Nominations
New White Paper Highlights How Closing the Health Information Gap Between Doctors and Patients Improves Life Science Marketing & Adds Value to Clinical Conversations
OptimizeRx Reports First Quarter 2024 Financial Results
Does OptimizeRx (OPRX) Have the Potential to Rally 34.78% as Wall Street Analysts Expect?
OptimizeRx to Participate in Upcoming Investor Conferences
OptimizeRx Provides Business Update and Sets First Quarter 2024 Conference Call for May 14, 2024 at 4:30 p.m. ET
After Plunging -22.84% in 4 Weeks, Here's Why the Trend Might Reverse for OptimizeRx (OPRX)
Down -18.75% in 4 Weeks, Here's Why You Should You Buy the Dip in OptimizeRx (OPRX)
OptimizeRx Releases 2024 Environmental, Social, and Governance (ESG) Report
OptimizeRx Named America’s Fastest-Growing Company for Fifth Year in a Row
OptimizeRx Sets Fourth Quarter 2023 Conference Call for March 28, 2024 at 8:30 a.m. ET
OptimizeRx Provides an Update on the Timing of Earnings Call and Reaffirms Prior Revenue and Adjusted EBITDA Estimates for FY2023
OptimizeRx Powers Walmart's ‘Specialty Pharmacies of the Community’ Outreach Effort
OptimizeRx to Participate in Upcoming Investor Conferences
Bruker (BRKR) Q4 Earnings and Revenues Top Estimates
OptimizeRx Announces Strategic Board Changes to Support Growth and Evolving Landscape
OptimizeRx Preannounces Select Expected 2023 Financials and Provides a Business Update
OptimizeRx to Participate at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco
OptimizeRx Corp. (OPRX) Upgraded to Buy: What Does It Mean for the Stock?
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 92.89M
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 96.06M
- P/E
P/E ratio compares a company's share price to its earnings per share.
- 13.59
- P/B
P/B ratio compares a company's share price to its book value per share.
- 0.72
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 0.87
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- 5.09
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 0.89
- EPS
- 0.36
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- 6.48
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- 6.46
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- 14.33M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- 5.27%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- 4.09%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0.18
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 5.37
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 5.37
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 1.93
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 488.08K
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 4.95
Income Statement
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Revenue | 19.84M | 32.24M | 26.07M | 29.2M | 21.93M |
| Gross profit | 14.93M | 24.1M | 17.52M | 18.64M | 13.34M |
| Operating income | 396K | 8.57M | 2.05M | 3.19M | -2.1M |
| EBITDA | 1.46M | 10.02M | 3.13M | 4.26M | -1.01M |
| Net income | -495K | 5.02M | 779K | 1.53M | -2.2M |
| Basic EPS | -0.03 | 0.27 | 0.04 | 0.08 | -0.12 |
| Diluted EPS | -0.03 | 0.26 | 0.04 | 0.08 | -0.12 |
Balance Sheet
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Total assets | 167.26M | 176.92M | 170.32M | 169.27M | 167.77M |
| Total liabilities | 37.65M | 48.62M | 48.06M | 49.98M | 51.5M |
| Total equity | 129.61M | 128.29M | 122.26M | 119.28M | 116.27M |
| Cash & equivalents | 20.17M | 23.37M | 19.52M | 16.59M | 16.57M |
| Current assets | 56.17M | 64.72M | 56.32M | 54.08M | 51.71M |
| Current liabilities | 10.46M | 21.26M | 18.47M | 21.06M | 18.35M |
Cash Flow
| Line Item | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 |
|---|---|---|---|---|---|
| Operating cash flow | -467K | 7.09M | 3.2M | 4.56M | 3.86M |
| Investing cash flow | -21K | 206K | -10K | -44K | -84K |
| Financing cash flow | -2.71M | -3.45M | -258K | -4.51M | -587K |
| Change in cash | -3.2M | 3.85M | 2.93M | 12K | 3.19M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | DEFA14A — OptimizeRx Corp | View Filing | |
| edgar index | 4 — OptimizeRx Corp | View Filing | |
| edgar index | 4 — OptimizeRx Corp | View Filing | |
| form 4 | Form 4 — Silvestro Stephen L | View Filing | |
| form 4 | Form 4 — Greco Theresa | View Filing | |
| form 4 | Form 4 — Greco Theresa | View Filing | |
| edgar index | 10-Q — OptimizeRx Corp | View Filing | |
| edgar index | 8-K — OptimizeRx Corp | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 3 — OptimizeRx Corp | View Filing | |
| edgar index | 8-K — OptimizeRx Corp | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 8-K — OptimizeRx Corp | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | SCHEDULE 13G/A — OptimizeRx Corp | View Filing | |
| edgar index | 10-K — OptimizeRx Corp | View Filing | |
| ten k section | 10-K — business | View Filing | |
| ten k section | 10-K — mda | View Filing | |
| ten k section | 10-K — risk_factors | View Filing | |
| edgar index | 8-K — OptimizeRx Corp | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| edgar index | 4 — OptimizeRx Corp | View Filing | |
| form 4 | Form 4 — Odence-Ford Marion | View Filing | |
| form 4 | Form 4 — Odence-Ford Marion | View Filing | |
| form 4 | Form 4 — Odence-Ford Marion | View Filing | |
| edgar index | 4/A — OptimizeRx Corp | View Filing | |
| edgar index | 4 — OptimizeRx Corp | View Filing | |
| edgar index | 4 — OptimizeRx Corp | View Filing | |
| edgar index | 4 — OptimizeRx Corp | View Filing | |
| edgar index | 4 — OptimizeRx Corp | View Filing | |
| edgar index | 4 — OptimizeRx Corp | View Filing | |
| edgar index | 4/A — OptimizeRx Corp | View Filing | |
| form 4 | Form 4 — Stelmakh Edward | View Filing | |
| form 4 | Form 4 — Besch Doug | View Filing | |
| form 4 | Form 4 — Odence-Ford Marion | View Filing | |
| form 4 | Form 4 — Silvestro Stephen L | View Filing | |
| form 4 | Form 4 — Greco Theresa | View Filing | |
| form 4 | Form 4 — Silvestro Stephen L | View Filing | |
| edgar index | 4 — OptimizeRx Corp | View Filing | |
| edgar index | 4 — OptimizeRx Corp | View Filing | |
| edgar index | 4 — OptimizeRx Corp | View Filing | |
| edgar index | 4 — OptimizeRx Corp | View Filing | |
| edgar index | 4 — OptimizeRx Corp | View Filing | |
| edgar index | 4 — OptimizeRx Corp | View Filing | |
| form 4 | Form 4 — Besch Doug | View Filing | |
| form 4 | Form 4 — Besch Doug | View Filing | |
| form 4 | Form 4 — Besch Doug | View Filing | |
| form 4 | Form 4 — D'Silva Andrew J. | View Filing | |
| form 4 | Form 4 — Merrell Brendan W. | View Filing | |
| form 4 | Form 4 — Odence-Ford Marion | View Filing | |
| form 4 | Form 4 — Odence-Ford Marion | View Filing | |
| form 4 | Form 4 — Odence-Ford Marion | View Filing | |
| form 4 | Form 4 — Silvestro Stephen L | View Filing | |
| form 4 | Form 4 — Silvestro Stephen L | View Filing | |
| form 4 | Form 4 — Silvestro Stephen L | View Filing | |
| form 4 | Form 4 — Stelmakh Edward | View Filing | |
| form 4 | Form 4 — Stelmakh Edward | View Filing | |
| form 4 | Form 4 — Stelmakh Edward | View Filing | |
| form 4 | Form 4 — Stelmakh Edward | View Filing | |
| form 4 | Form 4 — Stelmakh Edward | View Filing | |
| form 4 | Form 4 — Stelmakh Edward | View Filing | |
| edgar index | 4 — OptimizeRx Corp | View Filing | |
| edgar index | 4 — OptimizeRx Corp | View Filing | |
| form 4 | Form 4 — D'Silva Andrew J. | View Filing | |
| form 4 | Form 4 — Merrell Brendan W. | View Filing | |
| edgar index | 3 — OptimizeRx Corp | View Filing | |
| edgar index | 4 — OptimizeRx Corp | View Filing | |
| form 3 | Form 3 — Merrell Brendan W. | View Filing | |
| form 3 | Form 3 — Merrell Brendan W. | View Filing | |
| form 3 | Form 3 — Merrell Brendan W. | View Filing | |
| form 3 | Form 3 — Merrell Brendan W. | View Filing | |
| form 3 | Form 3 — Merrell Brendan W. | View Filing | |
| edgar index | 10-Q — OptimizeRx Corp | View Filing | |
| edgar index | 4 — OptimizeRx Corp | View Filing | |
| edgar index | 8-K — OptimizeRx Corp | View Filing |